Sinomune Pharmaceutical

About Sinomune Pharmaceutical

Sinomune Pharmaceutical Co., Ltd. is a Chinese pharmaceutical company founded in 1999 that specializes in dermatology and, to some extent, nephrology. Headquartered in Wuxi, China, the company operates as a private entity focused on the research and development, manufacturing, and sale of generic and innovative medicines, medical devices, and cosmetics.

The company's business model integrates online and offline channels to market its products across China. Sinomune generates revenue through multiple streams, including the sale of its branded products, contract development and manufacturing organization (CDMO/CMO) services for localizing topical drugs, and out-licensing its products. The firm also actively seeks to license-in or co-develop innovative drugs, medical devices, and skincare products to expand its portfolio. Its key product brands include LIFU for acne and rosacea, LUOFU for topical anti-fungal treatments, and JINUER for psoriasis. In April 2024, its Li Fu metronidazole gel, which uses Aptar Pharma's Airless+ drug delivery system, received approval from China's NMPA for treating papulopustular rosacea.

Sinomune operates a large-scale, automated production facility capable of producing 200 million units of topical formulations like creams, gels, and lotions annually, with plans to increase capacity. The company has a research center focused on topical dermatological formulations and has also conducted clinical trials for drugs related to kidney disease, such as Ferric Citrate for treating hyperphosphatemia.